Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Regeneron reports Pasatru data and Citi holds Regeneron stock

Analyst upgrade Clinical trial results AI-generated analysis

πŸ“ˆ Regeneron reported zero new lesions versus nine for placebo in the 84-week OPTIMA extension trial for Pasatru.

πŸ›‘οΈ Only one high-dose patient experienced a flare-up compared to 17 on placebo, indicating a favorable safety signal.

πŸ’° Q2 2026 revenue reached USD 4.29 billion, an increase from USD 3.68 billion in the year-earlier quarter.

πŸ“‰ Net profit declined to USD 1.30 billion from USD 1.39 billion despite strong top-line growth.

πŸ”¬ Phase 2 COURAGE data showed trevogrumab preserved nearly 70% of thigh muscle lost with semaglutide alone.

πŸ“Š Citi maintained a Hold rating on Regeneron stock with a USD 740.00 price target as of October 12, 2026.

πŸš€ Jefferies raised its Regeneron price target from USD 870.00 to USD 930.00 following recent clinical updates.

πŸ“… Third-quarter earnings are scheduled for October 30, 2026, before U.S. markets open.

Bullish Signals
  • Regeneron's Pasatru trial showed zero new lesions versus nine for placebo in the 84-week OPTIMA extension, confirming long-term efficacy.
  • The high-dose group recorded only one flare-up compared to 17 on placebo, highlighting a superior safety profile.
  • Q2 2026 revenue grew to USD 4.29 billion from USD 3.68 billion in the prior-year quarter, demonstrating strong commercial momentum.
  • Phase 2 COURAGE results demonstrated that trevogrumab preserved nearly 70% of thigh muscle mass lost with semaglutide alone.
Risk Factors
  • Net profit declined to USD 1.30 billion from USD 1.39 billion in the second quarter, raising questions about margin expansion despite revenue growth.
  • Skin and soft tissue infections occurred in 78% of patients on the high-dose Pasatru group, though all were resolved with management.
Full Analysis
Regeneron Pharmaceuticals reported positive Phase 3 OPTIMA extension data for its drug Pasatru on October 12, 2026. In the 84-week trial involving 63 adults with fibrodysplasia ossificans progressiva, the high-dose treatment resulted in zero new heterotopic ossification lesions compared to nine for placebo. Additionally, only one patient experienced a flare-up on the high dose versus 17 on placebo, demonstrating sustained efficacy and manageable safety profiles over the long term. The company also highlighted earlier Phase 2 COURAGE results where trevogrumab preserved nearly 70 percent of thigh muscle mass that would otherwise be lost with semaglutide alone. These clinical successes reinforce Regeneron's pipeline strength in rare diseases and metabolic conditions, providing a robust foundation ahead of its scheduled third-quarter earnings release on October 30, 2026. Financially, Regeneron generated USD 4.29 billion in revenue for the second quarter of 2026, representing growth from USD 3.68 billion in the prior-year period. However, net profit declined to USD 1.30 billion from USD 1.39 billion, creating investor interest in whether recent revenue expansion can translate into improved earnings margins during the upcoming quarterly report.